Fatty Liver Disease (NASH)




Fatty Liver Disease (NASH)

Official Title

Study of Safety and Efficacy of Tropifexor (LJN452) in Patients With Non-alcoholic Steatohepatitis (NASH)

Study Summary

The purpose of the study is to assess the effects of different doses of tropifexor (LJN452) with respect to safety, tolerability, and on markers of liver inflammation in patients with NASH.

Eligibility and Recruitment Information

Eligible Genders Both
Eligible Ages 18+
Inclusion NASH (Non-alcoholic Steatohepatitis), BMI above 27, elevated liver enzymes, and MRI compatible
Exclusion Cancer in the past 5 years, gastric surgery, cirrhosis, or heart issues
Start Date
Compensation Variable
Location Orlando, FL

Study Information

Condition Fatty Liver Disease (NASH)

Administrative Information

Study ID General Health

Apply for this study

Please include your first name.
Please include your last name.
Please include a valid email address.
Thank you for applying.
Sorry, something wen't wrong. Please contact us for support.